These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 34959116)
21. A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. Gulati A; Pomeranz C; Qamar Z; Thomas S; Frisch D; George G; Summer R; DeSimone J; Sundaram B Am J Med Sci; 2020 Jul; 360(1):5-34. PubMed ID: 32620220 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769 [TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596 [TBL] [Abstract][Full Text] [Related]
24. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. Bui NN; Lin YT; Huang SH; Lin CW Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355 [TBL] [Abstract][Full Text] [Related]
25. Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2). Rizwan K; Rasheed T; Khan SA; Bilal M; Mahmood T Hum Vaccin Immunother; 2020 Dec; 16(12):3001-3010. PubMed ID: 32881628 [TBL] [Abstract][Full Text] [Related]
26. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. Rohilla S Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381 [TBL] [Abstract][Full Text] [Related]
27. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination. Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876 [TBL] [Abstract][Full Text] [Related]
28. Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Lin Q; Lu C; Hong Y; Li R; Chen J; Chen W; Chen J Antiviral Res; 2022 Jul; 203():105345. PubMed ID: 35605699 [TBL] [Abstract][Full Text] [Related]
29. Challenges of vaccination and herd immunity in COVID-19 and management strategies. She J; Hou D; Chen C; Bi J; Song Y Clin Respir J; 2022 Nov; 16(11):708-716. PubMed ID: 36172975 [TBL] [Abstract][Full Text] [Related]
30. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
32. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM Front Immunol; 2021; 12():658519. PubMed ID: 34276652 [TBL] [Abstract][Full Text] [Related]
33. The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018 [TBL] [Abstract][Full Text] [Related]
34. Potential Drug Strategies to Target Coronaviruses. Sarkar K; Sil PC Adv Exp Med Biol; 2021; 1352():111-124. PubMed ID: 35132597 [TBL] [Abstract][Full Text] [Related]
35. Primed for global coronavirus pandemic: Emerging research and clinical outcome. Ahamad S; Branch S; Harrelson S; Hussain MK; Saquib M; Khan S Eur J Med Chem; 2021 Jan; 209():112862. PubMed ID: 33070079 [TBL] [Abstract][Full Text] [Related]
36. Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. Kovalenko A; Ryabchevskaya E; Evtushenko E; Nikitin N; Karpova O Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675218 [TBL] [Abstract][Full Text] [Related]
38. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119 [TBL] [Abstract][Full Text] [Related]
39. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Abd El-Aziz TM; Stockand JD Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825 [TBL] [Abstract][Full Text] [Related]
40. Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting. Abdirizak F; Lewis R; Chowell G Theor Biol Med Model; 2019 Oct; 16(1):16. PubMed ID: 31587665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]